Workshop organized by IABS

Scientific Committee

Tom Richie
The Sanaria Institute for Global Health & Tropical Medicine (SIGHTM)
Pieter Neels
Ana Older Aguilar
Bill & Melinda Gates Foundation
Christina Cassetti
National Institutes of Health
Beth Kirkpatrick
University of Vermont
Ivana Knezevic
World Health Organization
Matthew Laurens
University of Maryland
Mark Riddle
US Army Medical Research and Materiel Command
Meta Roestenberg
Leiden University Medical Center
Taryn Rogalski
Takeda Vaccines, Inc.
Zoe Seager
Wellcome Trust
Rebecca Sheets
Grimalkin Partners
Charlie Weller
Wellcome Trust
Adrian Wildfire
SGS - Life Sciences, United Kingdom

Meeting management:

Geneva, Switzerland

Objectives of the Workshop

Our world needs safer, more effective drugs and vaccines to prevent and treat infectious diseases. Controlled human infections (CHIs) have served as an effective tool to promote this objective. For example, CHIs have led to progress in developing interventions against respiratory pathogens (influenza, RSV, rhinovirus, pneumococcus), enteric pathogens (rotavirus infections, norovirus infections, cholera, shigellosis, ETEC infections, typhoidal infections, campylobacteriosis, helicobacteriosis), and parasites (malaria, giardiasis, hookworm infections). Based on the premise that optimal use of CHIs is one of the best, most efficient ways to achieve rapid progress against infectious diseases, IABS is hosting a workshop to review the use of HCTs to promote the development of new drugs and vaccines, the benefits and risks of this approach, the regulatory framework within which HCTs are conducted, and novel CHI applications that could open new translational pathways. This workshop follows two and a half years after the first such workshop hosted by IABS in Strasbourg, France, September 2014.